tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

JPMorgan adds PTC Therapeutics to Analyst Focus List after selloff

JPMorgan added PTC Therapeutics (PTCT) to the firm’s Analyst Focus List while keeping an Overweight rating on the shares with a $68 price target The selloff following the Complete Response Letter from the FDA for the Freidreich’s ataxia indication presents an attractive buying opportunity, the analyst tells investors in a research note. The firm is not surprised by the CRL and believes it is fully priced into the shares.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1